Purple Biotech Corporate Bonds and Leverage Analysis
| PPBT Stock | USD 2.70 0.10 3.57% |
Purple Biotech holds a debt-to-equity ratio of 0.01. . Purple Biotech's financial risk is the risk to Purple Biotech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Purple Biotech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Purple Biotech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Purple Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Purple Biotech's stakeholders.
For most companies, including Purple Biotech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Purple Biotech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Purple Biotech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Purple |
Given the importance of Purple Biotech's capital structure, the first step in the capital decision process is for the management of Purple Biotech to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Purple Biotech to issue bonds at a reasonable cost.
Purple Biotech Debt to Cash Allocation
Purple Biotech currently holds 183 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 6.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Purple Biotech's use of debt, we should always consider it together with its cash and equity.Purple Biotech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Purple Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Purple Biotech, which in turn will lower the firm's financial flexibility.Purple Biotech Corporate Bonds Issued
Understaning Purple Biotech Use of Financial Leverage
Purple Biotech's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Purple Biotech's current equity. If creditors own a majority of Purple Biotech's assets, the company is considered highly leveraged. Understanding the composition and structure of Purple Biotech's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.